Pipeline Overview
Our pipeline consists of both Metal Drug Complexes (MDCs) and Functional Drug Complexes (FDCs), each targeting specific clinical indications with programmable therapeutic mechanisms.
Metal Drug Complex (MDC) Pipeline
| Compound | Indication | Mechanism | Phase |
|---|---|---|---|
| Zn²⁺-Ivermectin | Antiviral | Viral protein affinity logic | Preclinical |
| Cu²⁺-Histidine | Neuroinflammation | ROS-gated metal delivery | Concept Validated |
| Ru⁴⁺-Doxorubicin | Oncology | TME-specific activation | Preclinical |
Ru⁴⁺-Doxorubicin Complex
Our Ru⁴⁺-Doxorubicin complex represents a new approach to targeted oncology. The ruthenium complex shields doxorubicin until it reaches the tumor microenvironment, where pH and redox changes trigger drug release.
Functional Drug Complex (FDC) Pipeline
| Complex Name | Indication | Mechanism | Phase |
|---|---|---|---|
| Peptide-RNA ImmunoMod | Autoimmune | RNA-guided peptide activation | Concept Validated |
| OncoLogic-FDC | Oncology | Glyco-tagged nanoshell delivery | Preclinical |
Peptide-RNA ImmunoMod
Our Peptide-RNA ImmunoMod presents a novel approach to autoimmune disease treatment. The complex uses RNA recognition motifs to guide peptide activity to specific immune cell types, allowing for precise immunomodulation without broad immune suppression.
Development Timeline
2024 Q1-Q2
Completion of in vitro studies for Ru⁴⁺-Doxorubicin and OncoLogic-FDC compounds.
2024 Q3-Q4
Initiation of animal studies for Zn²⁺-Ivermectin and preparation for IND-enabling studies.
2025 Q1-Q2
Expected completion of preclinical package for lead compounds and potential IND filing.
2025 Q3-Q4
Projected Phase 1 clinical trial initiation for first MDC compound.
Partner with MetalDrug
Our clinical pipeline is constantly evolving. We welcome partnerships with pharmaceutical companies, research institutions, and clinical investigators interested in advancing our compounds.